WO2020149636A1 - Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec - Google Patents

Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec Download PDF

Info

Publication number
WO2020149636A1
WO2020149636A1 PCT/KR2020/000725 KR2020000725W WO2020149636A1 WO 2020149636 A1 WO2020149636 A1 WO 2020149636A1 KR 2020000725 W KR2020000725 W KR 2020000725W WO 2020149636 A1 WO2020149636 A1 WO 2020149636A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry eye
syndrome
dry
eye syndrome
prevention
Prior art date
Application number
PCT/KR2020/000725
Other languages
English (en)
Korean (ko)
Inventor
김정현
Original Assignee
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교산학협력단 filed Critical 전북대학교산학협력단
Publication of WO2020149636A1 publication Critical patent/WO2020149636A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a pharmaceutical composition for the prophylaxis or treatment of dry eye syndrome comprising aucvin.
  • Dry eye syndrome causes damage to the eye surface by causing eye discomfort, deterioration of eyesight, and instability of the tear layer due to tear and inflammation of the eye surface (cornea and conjunctiva).
  • corneal ulcers There is a high risk of developing pain, irregular corneal surfaces, blurred and fluctuating vision, and corneal ulcers.
  • inflammation plays an important role, including infiltration of inflammatory cells, increased immune activation molecule and adhesion molecule expression, Th1 and Th17 responses, and abnormal changes in apoptosis markers and chemokines. have.
  • foods rich in potassium and anthocyanins are recommended for the treatment of dry eye syndrome.
  • Korean Patent Publication No. 10-2018-0065933 discloses a composition for preventing or treating inflammatory eye diseases comprising a maple leaf extract or a fraction thereof
  • Korean Patent No. 10-1910908 discloses Gly-T ⁇ 4
  • a pharmaceutical composition for treating dry eye syndrome containing (Gly-thymosin ⁇ 4) is disclosed.
  • Aucubin is a major component (Aucuba japonica) of the main tree (Aucuba japonica), the present inventors have confirmed the efficacy of the dry eye of the extract of the tree, while the active ingredient was confirmed while the increase in the secretion of tears and corneal drying damage , It was confirmed that it is possible to treat dry eye syndrome by suppressing corneal inflammation, thereby completing the present invention.
  • the present invention has been devised to solve the above problems, and while the present inventors are studying the composition for the prevention and treatment of dry eye syndrome, Aucubin increases the amount of tear secretion and prevents dryness of the cornea, and prevents dry eye through suppressing corneal inflammation. It was confirmed that can be treated, and the present invention was completed.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of dry eye syndrome, which comprises the acubin represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide a health functional food composition for the prevention or improvement of dry eye syndrome, which includes acubin represented by the following Chemical Formula 1.
  • Another object of the present invention is to provide a method for preventing or treating dry eye syndrome, comprising the step of administering aucoubin in a pharmaceutically effective amount to an individual in need thereof.
  • Another object of the present invention is to provide a use for use in the composition for preventing or treating dry eye syndrome.
  • the present invention can provide a pharmaceutical composition for the prevention or treatment of dry eye syndrome comprising an acubin represented by Formula 1 below or a pharmaceutically acceptable salt thereof:
  • composition can be administered orally.
  • the acubin may be included at a concentration of 1 mg/kg to 150 mg/kg.
  • composition is any one selected from the group consisting of solutions, suspensions, syrups, emulsions, liposomes, powders, powders, granules, tablets, sustained release preparations, eye drops, capsules, contact lens cleaners and contact lens lubricants It may be a formulation of.
  • the dry eye syndrome is anesthesia, corneal dryness, Sjogren's syndrome, dry corneal conjunctivitis, Stephen-Johnson syndrome, eye analog blisters, dry eye after ophthalmic surgery, dry eye with allergic conjunctivitis, VDT (Visual Display Terminal) It can be any one selected from the group consisting of dry eye-like conditions, including tear reduction in workers and without any systemic symptoms caused by dry rooms due to air conditioning.
  • the present invention can also provide a health functional food composition for the prevention or improvement of dry eye syndrome comprising acubin represented by the following Chemical Formula 1:
  • the acubin may be included at a concentration of 1 mg/kg to 150 mg/kg.
  • the dry eye syndrome is anesthesia, corneal dryness, Sjogren's syndrome, dry corneal conjunctivitis, Stephen-Johnson syndrome, eye analog blisters, dry eye after ophthalmic surgery, dry eye with allergic conjunctivitis, VDT (Visual Display Terminal) It can be any one selected from the group consisting of dry eye-like conditions, including tear reduction in workers and without any systemic symptoms caused by dry rooms due to air conditioning.
  • the present invention can provide a method for preventing or treating dry eye syndrome, comprising the step of administering aucoubin to a subject in need thereof in a pharmaceutically effective amount.
  • the present invention can provide a use for the use of aucvin in a composition for preventing or treating dry eye syndrome.
  • Aucubin of the present invention has no cytotoxicity at a concentration of 30 ⁇ g/mL in human corneal epithelial cells, reduces cell death under dry stress, and reduces the expression of genes of inflammation that promote dry eye syndrome.
  • it in the animal model inducing dry eye, it has an effect of increasing the secretion of tears, restoring damage due to drying of the cornea, and reducing cell death due to drying. Through this, there is an effect of treating, preventing, or improving acuvin's dry eye syndrome.
  • 1 is a result of confirming the cell viability after inducing dry stress by inducing dry stress by exposing air to the air after 24 hours pre-treatment and after confirming the cytotoxicity after 24 hours after concentration-dependent treatment of aqubin.
  • Figure 3 is a result of confirming the effect of aucoubin on inflammatory cytokines in human corneal epithelial cells by mRNA level
  • (A) is IL-1 ⁇
  • (B) is IL-8
  • (C) is TNF- ⁇ This is the result of confirming the mRNA level by PCR.
  • Figure 4 is a result of confirming the effect of acubin on the amount of tears and corneal damage in the dry eye animal model, (A) is a result of measuring the amount of tears, (B) is a result showing the state of the corneal surface, ( C) is the result of quantifying the result of (B).
  • Figure 5 is a result of confirming the effect of aqubin in apoptosis cells on the surface of the eye in the dry eye animal model, (A) is the result of TUNEL stained image, (B) is the result of quantifying the result of (A) .
  • Dry eye syndrome causes damage to the eye surface by causing eye discomfort, deterioration of eyesight, and instability of the tear layer due to tear and inflammation of the eye surface (cornea and conjunctiva). There is a high risk of developing pain, irregular corneal surfaces, blurred and fluctuating vision, and corneal ulcers.
  • inflammation plays an important role, including infiltration of inflammatory cells, increased immune activation molecule and adhesion molecule expression, Th1 and Th17 responses, and abnormal changes in apoptosis markers and chemokines. have.
  • treatments are used to control the amount of tears discharged by blocking artificial tears and tears.
  • dry eye syndrome is a common disease that occurs in about 20% of adults in Korea. Especially, the number of patients with dry eye syndrome continues to increase due to the rising temperature and environmental pollution due to global climate change, especially the El Ni ⁇ o phenomenon. There is no food.
  • the present inventors have studied the pharmaceutical composition for the prevention and treatment of dry eye syndrome, and confirmed that Aucubin has the effect of preventing and treating dry eye syndrome and completed the present invention.
  • Aucubin was not toxic to human corneal epithelial cells up to 30 ⁇ g/mL, and had an effect of increasing cell viability in an experiment inducing dry stress by exposure to air for 25 minutes (FIG. 1 ).
  • FIG. 1 As a result of confirming the death of cells under the dry stress through TUNEL staining, it was confirmed that the cells dying in the drying process were significantly reduced by pre-treatment with Aucubin (FIG. 2).
  • the present invention is to provide a pharmaceutical composition for the prevention or treatment of dry eye syndrome comprising an acubin (aucubin) represented by Formula 1 or a pharmaceutically acceptable salt thereof:
  • Alcubin (aucubin) is one of the physiologically active substances contained in the tree, it promotes uric acid excretion and is effective in gout, and is also effective in antioxidant by scavenging free radicals.
  • composition can be administered topically, transdermally, orally or parenterally, most preferably orally.
  • the acubin may be included at a concentration of 1 mg/kg to 150 mg/kg, preferably at a concentration of 1 mg/kg to 100 mg/kg, and most preferably 75 mg/kg.
  • composition is a formulation selected from the group consisting of solutions, suspensions, syrups, emulsions, liposomes, powders, powders, granules, tablets, sustained release preparations, eye drops, capsules, contact lens cleaners and contact lens lubricants Can.
  • the dry eye syndrome is anesthesia, corneal dryness, Sjogren's syndrome, dry corneal conjunctivitis, Stephen-Johnson syndrome, eye analog blisters, dry eye after ophthalmic surgery, dry eye with allergic conjunctivitis, VDT (Visual Display Terminal) It can be any one selected from the group consisting of dry eye-like conditions, including tear reduction in workers and without any systemic symptoms caused by dry rooms due to air conditioning.
  • the composition when it is a pharmaceutical composition, it may include a pharmaceutically acceptable diluent or carrier.
  • the diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, as a lubricant, magnesium stearate, talc, or a combination thereof.
  • the carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof.
  • the excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof.
  • the disintegrant may be carboxymethyl cellulose calcium, sodium starch glycolate, calcium monohydrogen phosphate anhydride, or a combination thereof.
  • the binder may be polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, or a combination thereof.
  • the lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
  • the pharmaceutical composition may contain the extract in an effective amount or as an active ingredient. The effective amount can be appropriately selected depending on the individual. The severity of the disease, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration, the route of administration and rate of excretion, the duration of treatment, factors including drugs used in combination with or concurrently with the composition and other medical fields. It can be determined according to well-known factors.
  • the composition may contain the extract in an effective amount or as an active ingredient depending on its use.
  • the effective amount can be appropriately selected depending on the individual.
  • the severity of the disease or condition, the age, weight, health, sex of the individual, sensitivity to the extract of the individual, time of administration, route of administration and rate of excretion, duration of administration, factors including other compositions combined with or concurrently used with the composition, and others It may be determined according to factors well known in the physiological or medical field.
  • the present invention can also provide a health functional food composition for the prevention or improvement of dry eye syndrome, which includes an acubin represented by Formula 1 below:
  • composition for a dietary supplement When the composition is a composition for a dietary supplement, it may be formulated into a formulation of a conventional dietary supplement known in the art.
  • the composition for health functional food may be prepared in general formulations such as powders, granules, tablets, pills, capsules, suspensions, emulsions, syrups, needles, liquids, ex-agents, meat, sausage, bread, chocolate, etc.
  • Candy, snacks, confectionery, pizza, ramen, other noodles, gums, jelly, dairy products including ice cream, various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes may be prepared in any form of health food. .
  • a food-acceptable carrier or additive may be used, and any carrier or additive known to be available in the art may be used for preparing a formulation to be prepared.
  • any carrier or additive known to be available in the art may be used for preparing a formulation to be prepared.
  • it may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
  • These additive components may be used independently or in combination, and the proportion of the additive may be 0.001 to 5% by weight, or 0.01 to 3% by weight based on the total weight of the composition.
  • the content of the acubin in the composition for health functional food may be appropriately determined according to the purpose of use (prevention or improvement). In general, it may contain from 0.01 to 15% by weight of the total food weight, and when prepared as a beverage, may contain 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 mL.
  • the beverage may further include other components other than the extract, and may further contain various flavoring agents or natural carbohydrates commonly used in beverages.
  • the natural carbohydrates include conventional sugars such as monosaccharides (eg glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), polysaccharides (eg, dextrin, cyclodextrin, etc.) and xylitol, sorbitol, erythritol, etc. Sugar alcohol may be contained.
  • a flavoring agent it may contain natural flavoring agents (eg, taumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.).
  • the proportion of the natural carbohydrate may be contained in about 1 to 20 g, preferably about 5 to 12 g per 100 mL of beverage.
  • the acubin may be included at a concentration of 1 mg/kg to 150 mg/kg, preferably at a concentration of 1 mg/kg to 100 mg/kg, and most preferably 75 mg/kg.
  • the dry eye syndrome is anesthesia, corneal dryness, Sjogren's syndrome, dry corneal conjunctivitis, Stephen-Johnson syndrome, eye analog blisters, dry eye after ophthalmic surgery, dry eye with allergic conjunctivitis, VDT (Visual Display Terminal) It can be any one selected from the group consisting of dry eye-like conditions, including tear reduction in workers and without any systemic symptoms caused by dry rooms due to air conditioning.
  • the present invention can provide a method for preventing or treating dry eye syndrome, comprising the step of administering aucoubin to a subject in need thereof in a pharmaceutically effective amount.
  • “individual” means a subject in need of treatment of a disease, and more specifically, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, mice, including humans, Means all animals, including rabbits or guinea pigs, and the above-mentioned diseases can be effectively prevented or treated by administering the pharmaceutical composition of the present invention to an individual.
  • the pharmaceutical composition of the present invention may be administered in parallel with existing therapeutic agents.
  • the present invention can provide a use for the use of aucvin in a composition for preventing or treating dry eye syndrome.
  • Corneal epithelial cells (PCS-700-010, American Type Culture Collection, Manassas, VA, USA) were prepared in corneal epithelial cell base medium containing growth supplements according to the manufacturer's instructions (American Type Culture Collection, Manassas, VA, USA). Cultured. Cell toxicity test was performed using the MTS assay kit (Promega Corporation). Cells (1 ⁇ 10 4 ) were grown in 96-well plates and then treated with aucubin at 0.1-30 ⁇ g/mL. Cytotoxicity was measured 24 hours after culture. As a result of the MTS analysis, absorbance was measured at 490 nm using a microplate reader (Tecan Group Ltd., Mannedorf, Switzerland). As a result, it was confirmed that acuvin had no cytotoxicity up to 30 ⁇ g/mL (FIG. 1 ).
  • the viability of dried cells was measured using an MTS assay kit. Aucubin was pretreated for 24 hours. The medium was then removed and exposed to air for 25 minutes to induce dry stress. Thereafter, as a result of experimenting cell survival with the method of Example 1, aucvin increased cell viability under dry stress in a dose-dependent manner (FIG. 1B ). To detect cell death cells after drying, the cells were grown on autoclaved cover slips. After pre-incubation of aucubin for 24 hours, the cells were exposed to dryness for 25 minutes and cell death was detected by TUNEL staining. The number of dying cells increased during the drying process, and the killing cells were significantly decreased in the 15 ⁇ g/mL acubin treatment group (FIGS. 2A and B ).
  • RNA expression of IL-1 ⁇ , IL-8 and TNF- ⁇ was significantly increased in the dry state and decreased by aucvin treatment (FIGS. 3A to 3C ).
  • the amount of tear secretion was measured by contacting the phenol-red thread tear level test paper (FCI Opthalmics Zone Quick, Japan) to the ocular surface at the outer end of the eyelid, and measuring the amount of tear secretion by measuring the length of the color change of the test paper by tears after 30 seconds. .
  • the dry eye model showed a lower amount of tears than the normal group, but recovered normally with aucvin treatment (Fig. 4).
  • the dryness damage of the cornea was analyzed by evaluating the degree of distortion caused by the dryness damage of the cornea of the circular illumination after photographing the reflection type by shining a circular illuminator (ring type light illuminator) on the cornea.
  • the dry eye model showed irregular circular light, but improved in the group treated with Aucubin (Fig. 4B).
  • the score of corneal staining showed a high score in the dry eye group, but the acubin treatment group confirmed that the score was low (FIG. 4C ).
  • Tissue apoptotic cells were measured using terminal deoxyribonucleotide transfer enzyme (TdT)-mediated dUTP nick end labeling (TUNEL) staining according to the manufacturer's instructions.
  • TdT terminal deoxyribonucleotide transfer enzyme
  • TUNEL dUTP nick end labeling

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec.
PCT/KR2020/000725 2019-01-15 2020-01-15 Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec WO2020149636A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0005417 2019-01-15
KR1020190005417A KR101978624B1 (ko) 2019-01-15 2019-01-15 아우쿠빈을 포함하는 안구건조증의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
WO2020149636A1 true WO2020149636A1 (fr) 2020-07-23

Family

ID=66581105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/000725 WO2020149636A1 (fr) 2019-01-15 2020-01-15 Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec

Country Status (2)

Country Link
KR (1) KR101978624B1 (fr)
WO (1) WO2020149636A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749984C1 (ru) * 2020-09-08 2021-06-21 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения синдрома сухого глаза у больных сахарным диабетом

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101978624B1 (ko) * 2019-01-15 2019-05-14 전북대학교산학협력단 아우쿠빈을 포함하는 안구건조증의 예방 또는 치료용 약학적 조성물
KR102172497B1 (ko) * 2019-12-27 2020-10-30 전북대학교산학협력단 아우쿠빈을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522120A (ja) * 1998-08-06 2002-07-23 エヌディティ インコーポレイテッド コンタクトレンズ溶液及び眼科用液剤
KR20070055952A (ko) * 2005-11-28 2007-05-31 주식회사 엠디바이오알파 안구건조증 치료 및 예방용 조성물
KR20150123152A (ko) * 2014-04-23 2015-11-03 경희대학교 산학협력단 어큐빈을 포함하는 신경줄기세포 또는 신경전구세포 분화 촉진용 조성물
KR101849301B1 (ko) * 2018-01-29 2018-04-16 전북대학교 산학협력단 식나무 추출물을 포함하는 안구 건조증 예방 또는 치료용 조성물
KR101978624B1 (ko) * 2019-01-15 2019-05-14 전북대학교산학협력단 아우쿠빈을 포함하는 안구건조증의 예방 또는 치료용 약학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522120A (ja) * 1998-08-06 2002-07-23 エヌディティ インコーポレイテッド コンタクトレンズ溶液及び眼科用液剤
KR20070055952A (ko) * 2005-11-28 2007-05-31 주식회사 엠디바이오알파 안구건조증 치료 및 예방용 조성물
KR20150123152A (ko) * 2014-04-23 2015-11-03 경희대학교 산학협력단 어큐빈을 포함하는 신경줄기세포 또는 신경전구세포 분화 촉진용 조성물
KR101849301B1 (ko) * 2018-01-29 2018-04-16 전북대학교 산학협력단 식나무 추출물을 포함하는 안구 건조증 예방 또는 치료용 조성물
KR101978624B1 (ko) * 2019-01-15 2019-05-14 전북대학교산학협력단 아우쿠빈을 포함하는 안구건조증의 예방 또는 치료용 약학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG, W. S. ET AL.: "Aucuba japonica extract and aucubin prevent desiccating stress-induced corneal epithelial cell injury and improve tear secretion in a mouse model of dry eye disease", MOLECULES, vol. 23, no. 2599, 11 October 2018 (2018-10-11), pages 1 - 10, XP055726314 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749984C1 (ru) * 2020-09-08 2021-06-21 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения синдрома сухого глаза у больных сахарным диабетом

Also Published As

Publication number Publication date
KR101978624B1 (ko) 2019-05-14

Similar Documents

Publication Publication Date Title
WO2020149636A1 (fr) Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec
WO2022154356A1 (fr) Composition comprenant le principe actif (7s)-(+)-acide cyclopentyl carbarmique, 8,8-diméthyl-2-oxo-6,7-dihydro-2h,8h-pyrano[3,2-g]chromen-7-yl-ester pour la prévention, le soulagement ou le traitement d'une maladie oculaire
WO2015026114A1 (fr) Composition contenant un composé monoacétyldiglycéride en tant que principe actif pour la prévention ou le traitement de l'arthrite rhumatoïde
WO2018117659A1 (fr) Composition pharmaceutique comprenant un extrait de levis pulverata indigo ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une maladie intestinale inflammatoire
WO2021256793A1 (fr) Composition comprenant une vésicule dérivée de bactérie lactobacillus pour la prévention ou le traitement d'une maladie métabolique ou d'une maladie musculaire
WO2024106716A1 (fr) Composition pour atténuer ou traiter la démence, contenant du 2'-fucosyllactose
WO2015026123A1 (fr) Composition contenant un composé monoacétyldiacylglycérol comme principe actif pour la prévention ou le traitement de maladies pulmonaires obstructives chroniques
WO2020231198A1 (fr) Composition permettant de prévenir ou de traiter une maladie rétinienne contenant un extrait de gypénoside
WO2018093237A2 (fr) Composition comprenant de l'acide formique ou un sel pharmaceutiquement acceptable de celui-ci comme principe actif pour la prévention ou le traitement de l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2021045569A1 (fr) Composition contenant de l'extrait de myrtille en tant que principe actif pour prévenir ou traiter une perte auditive neurosensorielle
JP2020505065A (ja) 植物由来の有効成分に基づく、眼保護作用を有する組成物
WO2018230942A1 (fr) Composition contenant un extrait ou une fraction d'extrait de reynoutria japonica pour prévenir et traiter le syndrome de l'œil sec
WO2022203251A1 (fr) Composition complexe pour la prévention ou le traitement de la perte auditive contenant du sarpogrelate et un extrait de vaccinium myrtillus en tant que principes actifs
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2013085351A1 (fr) Composition pharmaceutique comprenant une diaminodiphénylsulfone ou ses sels pharmaceutiquement acceptables et permettant de prévenir ou de traiter des maladies associées à l'atrophie musculaire
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2012033261A1 (fr) Composition pharmaceutique pour prévention ou traitement de la septicémie, contenant de la génipine ou un dérivé de celle-ci
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2022235021A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'une kérato-conjonctivite sèche et d'une maladie ophtalmologique liée à la kérato-conjonctivite sèche
WO2024090941A1 (fr) Composition de prévention, d'atténuation ou de traitement d'une maladie du segment antérieur de l'œil, comprenant comme principe actif un extrait végétal du genre aloe
WO2018080158A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'un trouble cognitif, contenant un extrait d'elaeagnus glabra en tant que principe actif
WO2013100292A1 (fr) Composition pour la prévention ou le traitement du diabète ou de complications du diabète
WO2024210505A1 (fr) Composition contenant un extrait de dolichos lablab linne en tant que principe actif pour la prévention, l'amélioration ou le traitement de maladies respiratoires allergiques
WO2020145728A1 (fr) Composition pour le traitement ou la prévention de la cataracte diabétique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20741310

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20741310

Country of ref document: EP

Kind code of ref document: A1